| Latest YM Biosciences News Headlines | | Date | Time | Source | | | 11/13/2008 | 10:44AM | PRNUS | BBM Announces Offer to Acquire YM BioSciences Inc.
NEW YORK, Nov. 13 /PRNewswire-FirstCall/ -- BBM Holdings (OTC Bulletin Board: BBMO) announced today that it has made an offer to acquire YM BioSciences Inc. (AMEX:YMI) by a letter to YMI's Chief Executive Officer, Dr. David Allan.
Under BBM's proposal, BBM would acquire in a merger all of the outstanding shares of... More...>> |
| 08/05/2008 | 9:46AM | PRNUS | NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
MISSISSAUGA, ON, Aug. 5 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, will hold a conference call hosted by Mr. David Allan, Chairman and CEO, at 12:00pm EDT... More...>> |
| 08/04/2008 | 7:23PM | PRNUS | YM BIOSCIENCES REPORTS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
- Overall Survival And Disease Control Outcomes, Coupled With Low Toxicity, Support The Continued Development Of The EGFR Antibody In Patients With Colorectal Cancer -
MISSISSAUGA, ON, Aug. 4 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology company that identifies... More...>> |
| 06/19/2008 | 5:00PM | PRNUS | YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL
- Dr. Ali Raza To Lead Further Development Of AeroLEF As President Of AeroLEF Division -
MISSISSAUGA, ON, June 19 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide... More...>> |
| 06/03/2008 | 1:57PM | PRNUS | NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that clinical data from three clinical trials of its anti-cancer drug nimotuzumab... More...>> |
| 04/11/2008 | 5:07PM | PRNUS | YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
MISSISSAUGA, ON, April 11 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that posters describing research conducted on two of its anti-cancer drugs... More...>> |
| 01/17/2008 | 1:00AM | PRNUS | YM BioSciences provides update on AeroLEF(TM) clinical development program
MISSISSAUGA, ON, Jan. 17 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that it has received a letter from the U.S. Food and Drug Administration... More...>> |
| 12/20/2007 | 11:15AM | PRNUS | YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
MISSISSAUGA, ON, Dec. 20 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that it has completed accrual in the first 50-patient cohort of its Phase... More...>> |
| 11/12/2007 | 1:00AM | PRNUS | YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
MISSISSAUGA, ON, Nov. 12 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:YMAMEX:AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported operational and financial results for the first quarter of fiscal 2008, ended September... More...>> |
| 10/22/2007 | 5:00PM | PRNUS | YM Biosciences announces adoption of renewed Shareholders' Rights Plan
MISSISSAUGA, ON, Oct. 22 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that its Board of Directors has adopted a renewed Shareholder Rights Plan... More...>> |
| 10/11/2007 | 1:30PM | PRNUS | YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND NOMINATION OF DIRECTORS
MISSISSAUGA, ON, Oct. 11 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:YMAMEX:AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today advised that its Annual Meeting of Shareholders will take place on November 28th, 2007 at 4:00pm... More...>> |
| 09/24/2007 | 1:00AM | PRNUS | YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS
MISSISSAUGA, ON, Sept. 24 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:YMAMEX:AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported operational and financial results for the fourth quarter and the 2007 fiscal year... More...>> |
| 09/20/2007 | 3:30PM | PRNUS | YM BIOSCIENCES NOTICE OF CONFERENCE CALL TO ANNOUNCE FOURTH QUARTER AND YEAR-END FISCAL 2007 FINANCIAL RESULTS
MISSISSAUGA, ON, Sept. 20 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), will release its fiscal 2007 financial results on Monday, September 24, 2007 at 1:00AM (EDT) (6:00AM BST). The announcement will be followed by a conference call at 9:00AM (EST), hosted by David Allan... More...>> |
| 09/04/2007 | 5:02PM | PRNUS | YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
Data Presented at the 12th World Conference on Lung Cancer in Seoul, Korea
MISSISSAUGA, ON, Sept. 4 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced... More...>> |
| 08/30/2007 | 5:00PM | PRNUS | YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent b
MISSISSAUGA, ON, Aug. 30 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that its wholly-owned US subsidiary, YM BioSciences USA Inc. ("YM-USA... More...>> |
| 08/21/2007 | 7:00AM | PRNUS | YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCR
MISSISSAUGA, ON, Aug. 21 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that Oncoscience AG (Wedel, Germany), its European partner for the development... More...>> |
| 08/17/2007 | 5:00PM | PRNUS | YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
MISSISSAUGA, ON, Aug. 17 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:YMAMEX:AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announces that the information required to be disclosed in accordance with Rule 26 of the AIM... More...>> |
| 08/15/2007 | 7:00AM | PRNUS | ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRI
MISSISSAUGA, ON, Aug. 15 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that Oncoscience AG (Wedel, Germany), its European partner for the development... More...>> |
| 07/31/2007 | 2:30PM | PRNUS | YM BioSciences Initiates Patient Enrolment In Phase II Colorectal Cancer Trial With EGFR Antibody
MISSISSAUGA, ON, July 31 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that it has enrolled the first five patients within the 50-patient initial... More...>> |
| 07/11/2007 | 7:00AM | PRNUS | YM BIOSCIENCES ANNOUNCES SECONDARY EFFICACY AND SAFETY FINDINGS IN RANDOMIZED PHASE IIB AEROLEF(TM) TRIAL
- Company Announces Lead Investigator for U.S. Trial -
MISSISSAUGA, ON, July 11 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (AMEX:YMIAMEX:TSX:AMEX:YMAMEX:AIM:AMEX:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced results of secondary... More...>> |
|